Generic Name: NIACIN EXTENDED-RELEASE/SIMVASTATIN - ORAL Pronounced: (NYE-a-sin/SIM-va-STAT-in) Niacin-simvastatin Oral Precautions
Before taking this product, tell your doctor or pharmacist
if you are allergic to niacin or simvastatin; or if you have any other
allergies. This product may contain inactive ingredients, which can cause
allergic reactions or other problems. Talk to your pharmacist for more
Before using this medication, tell your doctor or
pharmacist your medical history, especially of:
Before having surgery, tell your doctor or dentist about
all the products you use (including prescription drugs, nonprescription drugs,
and herbal products).
This drug may make you dizzy. Do not drive, use machinery,
or do any activity that requires alertness until you are sure you can perform
Several days, ago, it was discussed in the New Jersey Star-Ledger. Then the New York Times. So I guess it's my turn. The New Jersey paper frequently reports and editorializes on drug company problems. No big surprise, as many drug companies are in NJ -- including Schering-Plough and Merck, who have had a recent egg-on-their-face episode with delayed reporting of a study involving Vytorin and Zetia. But then the New York Times chimed in the next day (April 2) with an editorial, Overpromoted Cholesterol Drugs . The Times editorialized that "It is distressingly late to be learning that these drugs may provide little or no benefit." Time to clear up the air... sorry, NY Times, but they do have benefit, although a small study came to inconclusive results about their effects on some biomarkers. Seems that Schering Plough and Merck have been co-marketing a combination drug for hyperlipidemia, called Vytorin. Vytorin is a combination of two ingredients: Zetia (ezetimibe) and Zocor (...
The makers of Vytorin®, Merck/Schering-Plough Pharmaceuticals, recently issued a controversial press release about the Enhance Study that compared the effects of Vytorin® (a combination of simvastatin and ezetimibe, brand name Zetia®) vs. just simvastatin. No substantial difference was observed with the addition of Zetia®, perhaps even a negative effect. The news has triggered a media frenzy. The New York Times headlined the story, " Drug Has No Benefit in Trial ." "Drug doesn't slow artery clogs," declares the Washington Post . A medical marketing website declared "Vytorin study's a stinker." This has been followed by some journalists and scientists calling the entire lipid hypothesis , the notion that high cholesterol forms atherosclerotic plaque and heart disease, into doubt. "New Questions on Treating Cholesterol" ( http://www.nytimes.com/2008/01/17/business/17drug.html?ex=1358312400&en=11b68f069a83f57c&a...
You should knowAnswers to your question are meant to provide general health information but should not replace medical advice you receive from a doctor. No answers should be viewed as a diagnosis or recommended treatment for a condition. Content posted by community members does not necessarily reflect the views of Remedy Health Media, which also reserves the right to remove material deemed inappropriate.